[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1037500, "exercisedValue": 0, "unexercisedValue": 9922011}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 55, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 35, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1989, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tommy  Diraimondo Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  Mciver", "title": "Vice President of Clinical Development.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 44.59, "open": 44.71, "dayLow": 42.91, "dayHigh": 45.44, "regularMarketPreviousClose": 44.59, "regularMarketOpen": 44.71, "regularMarketDayLow": 42.91, "regularMarketDayHigh": 45.44, "beta": 3.517, "forwardPE": -19.84952, "volume": 1087671, "regularMarketVolume": 1087671, "averageVolume": 1140818, "averageVolume10days": 1221930, "averageDailyVolume10Day": 1221930, "bid": 32.43, "ask": 55.46, "bidSize": 200, "askSize": 200, "marketCap": 2586292736, "fiftyTwoWeekLow": 7.79, "fiftyTwoWeekHigh": 71.71, "priceToSalesTrailing12Months": 198.19853, "fiftyDayAverage": 52.3501, "twoHundredDayAverage": 48.049625, "currency": "USD", "enterpriseValue": 1680281216, "floatShares": 38001102, "sharesOutstanding": 58632800, "sharesShort": 7678286, "sharesShortPriorMonth": 4477253, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.131, "heldPercentInsiders": 0.07225, "heldPercentInstitutions": 0.86257005, "shortRatio": 4.79, "shortPercentOfFloat": 0.2337, "impliedSharesOutstanding": 58632800, "bookValue": 12.537, "priceToBook": 3.5183856, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -60536000, "trailingEps": -1.17, "forwardEps": -1.6, "enterpriseToRevenue": 128.767, "enterpriseToEbitda": -20.031, "52WeekChange": 3.6334033, "SandP52WeekChange": 0.23809385, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "JANX", "underlyingSymbol": "JANX", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "firstTradeDateEpochUtc": 1623418200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "3a638123-d3da-3133-96c7-e6e8cabf84b3", "messageBoardId": "finmb_676965261", "gmtOffSetMilliseconds": -18000000, "currentPrice": 44.11, "targetHighPrice": 200.0, "targetLowPrice": 25.0, "targetMeanPrice": 89.07692, "targetMedianPrice": 81.0, "recommendationKey": "none", "numberOfAnalystOpinions": 13, "totalCash": 658030976, "totalCashPerShare": 12.539, "ebitda": -83883000, "totalDebt": 23431000, "quickRatio": 38.577, "currentRatio": 38.801, "totalRevenue": 13049000, "debtToEquity": 3.571, "revenuePerShare": 0.255, "returnOnAssets": -0.09932, "returnOnEquity": -0.120459996, "grossProfits": -46774000, "freeCashflow": -21559250, "operatingCashflow": -36990000, "revenueGrowth": -0.826, "operatingMargins": -81.644646, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]